Tango Therapeutics Inc

NASDAQ:TNGX 4:00:00 PM EDT

7.31

0.00 (0.00%)

5:54:53 PM EDT: $7.50 +0.19 (+2.60%)

Market Cap (Intraday)	780.11M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$7.87 Million
Adjusted EPS	-$0.31

See more estimates

10-Day MA	$7.41
50-Day MA	$9.32
200-Day MA	$8.49

See more pivots

Tango Therapeutics Inc Stock, NASDAQ:TNGX

201 Brookline Avenue, Suite 901, Boston, Massachusetts 02215

United States of America

Phone: +1.857.320.4900

Number of Employees: 140

http://www.tangotx.com

Description

Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. It also identifies novel targets and develops new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. The company was founded by Alan Ashworth, William G. Kaelin, Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Boston, MA.